| Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial C Koh, L Canini, H Dahari, X Zhao, SL Uprichard, V Haynes-Williams, ... The Lancet Infectious Diseases 15 (10), 1167-1174, 2015 | 308 | 2015 |
| Rates of and factors associated with placebo response in trials of pharmacotherapies for nonalcoholic steatohepatitis: systematic review and meta-analysis MAT Han, O Altayar, S Hamdeh, V Takyar, Y Rotman, O Etzion, ... Clinical Gastroenterology and Hepatology 17 (4), 616-629. e26, 2019 | 133 | 2019 |
| MR elastography‐based liver fibrosis correlates with liver events in nonalcoholic fatty liver patients: a multicenter study MAT Han, A Vipani, N Noureddin, K Ramirez, J Gornbein, R Saouaf, ... Liver International 40 (9), 2242-2251, 2020 | 66 | 2020 |
| Magnetic resonance elastography shear wave velocity correlates with liver fibrosis and hepatic venous pressure gradient in adults with advanced liver disease AM Gharib, MAT Han, EG Meissner, DE Kleiner, X Zhao, M McLaughlin, ... BioMed Research International 2017 (1), 2067479, 2017 | 52 | 2017 |
| Magnetic resonance imaging and transient elastography in the management of Nonalcoholic Fatty Liver Disease (NAFLD) MAT Han, R Saouaf, W Ayoub, T Todo, E Mena, M Noureddin Expert review of clinical pharmacology 10 (4), 379-390, 2017 | 45 | 2017 |
| Diversity in NAFLD: a review of manifestations of nonalcoholic fatty liver disease in different ethnicities globally MAT Han, Q Yu, Z Tafesh, N Pyrsopoulos Journal of Clinical and Translational Hepatology 9 (1), 71, 2020 | 34 | 2020 |
| The balance of type 1 and type 2 immune responses in the contexts of hepatitis B infection and hepatitis D infection EC Townsend, GY Zhang, R Ali, M Firke, MS Moon, MAT Han, B Fram, ... Journal of gastroenterology and hepatology 34 (4), 764-775, 2019 | 21 | 2019 |
| Noninvasive tests (NITs) for hepatic fibrosis in fatty liver syndrome MAT Han Life 10 (9), 198, 2020 | 18 | 2020 |
| Pharmacokinetics and pharmacodynamics modeling of lonafarnib in patients with chronic hepatitis delta virus infection L Canini, C Koh, SJ Cotler, SL Uprichard, MA Winters, MAT Han, ... Hepatology communications 1 (4), 288-292, 2017 | 12 | 2017 |
| Accounting for the placebo effect and optimizing outcomes in clinical trials of nonalcoholic steatohepatitis (NASH) N Noureddin, MAT Han, N Alkhouri, M Noureddin Current Hepatology Reports 19, 63-69, 2020 | 10 | 2020 |
| A randomized, proof-of-concept clinical trial on repurposing chlorcyclizine for the treatment of chronic hepatitis C C Koh, P Dubey, MAT Han, PJ Walter, HM Garraffo, P Surana, ... Antiviral research 163, 149-155, 2019 | 9 | 2019 |
| 392 post-infectious irritable bowel syndrome in patients undergoing fecal microbiota transplantation for recurrent Clostridium difficile colitis S Garg, Y Song, MAT Han, M Girotra, WF Fricke, S Dutta Gastroenterology 5 (146), S-83-S-84, 2014 | 9 | 2014 |
| Microbial translocation in the context of hepatitis B infection and hepatitis D infection EC Townsend, GY Zhang, R Ali, P Surana, M Firke, MS Moon, MAT Han, ... Open Forum Infectious Diseases 8 (11), ofaa496, 2021 | 7 | 2021 |
| Liver functional assessment by dual cholate testing is strongly correlated with direct portal pressure and Ishak fibrosis stage O Etzion, R Ali, GY Zhang, EC Townsend, C Koh, E Levy, VK Takyar, ... Hepatology 66, 1036A-1037A, 2017 | 7 | 2017 |
| Emerging therapies for alcoholic hepatitis MAT Han, N Pyrsopoulos Clinics in Liver Disease 25 (3), 603-624, 2021 | 6 | 2021 |
| Characterization of hepatic dysfunction in subjects diagnosed with Chronic GVHD by NIH consensus criteria AH Yang, MAT Han, N Samala, BS Rizvi, R Marchalik, O Etzion, ... Transplantation and cellular therapy 28 (11), 747. e1-747. e10, 2022 | 5 | 2022 |
| De novo and recurrence of metabolic dysfunction-associated fatty liver disease after liver transplantation MAT Han, R Olivo, CJ Choi, N Pyrsopoulos World Journal of Hepatology 13 (12), 1991, 2021 | 5 | 2021 |
| Disparities among ethnic groups in mortality and outcomes among adults with MASLD: A multicenter study MB Aboona, C Faulkner, P Rangan, CH Ng, DQ Huang, M Muthiah, ... Liver International 44 (6), 1316-1328, 2024 | 4 | 2024 |
| Current trends in liver transplantation for alcoholic hepatitis S Bhatti, D Kim, A Ahmed, G Cholankeril Clinics in Liver Disease 25 (3), 625-634, 2021 | 4 | 2021 |
| Fibrosis changes in the placebo arm of NASH clinical trials O Altayar, N Noureddin, MAT Han, MH Murad, M Noureddin Clinical Gastroenterology and Hepatology 17 (11), 2387, 2019 | 4 | 2019 |
